Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer

References

• Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23.
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Ordóñez-Morán P, Allegrucci C. Challenges for triple negative breast cancer treatment: defeating heterogeneity and cancer stemness. Cancers. 2022;14(17):4280. doi:10.3390/cancers14174280
   PubMed Web of Science ®Google Scholar
• Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11(8):808. doi:10.3390/jpm11080808
   PubMed Web of Science ®Google Scholar
• Moran MS. Radiation therapy in the locoregional treatment of triple-negative breast cancer. Lancet Oncol. 2015;16(3):e113–e122. doi:10.1016/S1470-2045(14)71104-0
   PubMed Web of Science ®Google Scholar
• Ahmed M, Jozsa F, Douek M. A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer. Ecancermedicalscience. 2021;15:1175. doi:10.3332/ecancer.2021.1175
   PubMed Web of Science ®Google Scholar
• Sousa C, Cruz M, Neto A, et al. Neoadjuvant radiotherapy in the approach of locally advanced breast cancer. ESMO Open. 2020;4(Suppl 2):e000640.
   PubMedGoogle Scholar
• Bhat V, Pellizzari S, Allan AL, et al. Radiotherapy and radiosensitization in breast cancer: molecular targets and clinical applications. Crit Rev Oncol Hematol. 2022;169:103566. doi:10.1016/j.critrevonc.2021.103566
   PubMed Web of Science ®Google Scholar
• Ahmad SS, Crittenden MR, Tran PT, et al. Clinical development of novel drug-radiotherapy combinations. Clin Cancer Res. 2019;25(5):1455–1461. doi:10.1158/1078-0432.CCR-18-2466
   PubMed Web of Science ®Google Scholar
• Sharma RA, Plummer R, Stock JK, et al. Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol. 2016;13(10):627–642.
   PubMed Web of Science ®Google Scholar
• Parsyan A, Cruickshank J, Hodgson K, et al. Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer. Breast. 2021;58:6–9. doi:10.1016/j.breast.2021.03.011
   PubMed Web of Science ®Google Scholar
• Huang R-X, Zhou P-K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5(1):60. doi:10.1038/s41392-020-0150-x
   PubMed Web of Science ®Google Scholar
• Alam MS, Sultana A, Wang G, Haque Mollah MN. Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer. Front Mol Biosci. 2022;9:1049741. doi:10.3389/fmolb.2022.1049741
   PubMed Web of Science ®Google Scholar
• Tchatchou S, Wirtenberger M, Hemminki K, et al. Aurora kinases A and B and familial breast cancer risk. Cancer Lett. 2007;247(2):266–272. doi:10.1016/j.canlet.2006.05.002
   PubMed Web of Science ®Google Scholar
• Yuan K, Wu M, Lyu S, Li Y. Identification of prognostic genes for early basal-like breast cancer with weighted gene co-expression network analysis. Medicine. 2022;101(42):e30581. doi:10.1097/MD.0000000000030581
   PubMed Web of Science ®Google Scholar
• Liu M, Li Y, Zhang C, Zhang Q. Role of Aurora kinase B in regulating resistance to paclitaxel in breast cancer cells. Hum Cell. 2022;35(2):678–693. doi:10.1007/s13577-022-00675-8
   PubMed Web of Science ®Google Scholar
• Ahmed A, Shamsi A, Mohammad T, Hasan GM, Islam A, Hassan MI. Aurora B kinase: a potential drug target for cancer therapy. J Cancer Res Clin Oncol. 2021;147(8):2187–2198. doi:10.1007/s00432-021-03669-5
   PubMed Web of Science ®Google Scholar
• Gully CP, Zhang F, Chen J, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010;9(1):42. doi:10.1186/1476-4598-9-42
   PubMedGoogle Scholar
• Falchook GS, Bastida CC, Kurzrock R. Aurora kinase inhibitors in oncology clinical trials: current state of the progress. Semin Oncol. 2015;42(6):832–848. doi:10.1053/j.seminoncol.2015.09.022
   PubMed Web of Science ®Google Scholar
• Zhang J, Lin X, Wu L, et al. Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene. 2020;39(12):2550–2567. doi:10.1038/s41388-020-1165-z
   PubMed Web of Science ®Google Scholar
• Niermann KJ, Moretti L, Giacalone NJ, et al. Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res. 2011;175(4):444–451. doi:10.1667/RR2317.1
   PubMed Web of Science ®Google Scholar
• Tao Y, Leteur C, Calderaro J, et al. The Aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle. 2009;8(19):3172–3181. doi:10.4161/cc.8.19.9729
   PubMed Web of Science ®Google Scholar
• Tao Y, Zhang P, Girdler F, et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene. 2008;27(23):3244–3255. doi:10.1038/sj.onc.1210990
   PubMed Web of Science ®Google Scholar
• Jungles KM, Wang Z, Bishop C, et al. Targeting Aurora kinase B (AURKB) as a radiosensitizing strategy in syngeneic models of triple negative breast cancer (TNBC) (Abstract 708). Cancer Resear. 2024;84(6_Supplement):708. doi:10.1158/1538-7445.AM2024-708
   Google Scholar
• Mason JM, Lin DC, Wei X, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014;26(2):163–176. doi:10.1016/j.ccr.2014.05.006
   PubMed Web of Science ®Google Scholar
• Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50(W1):W739–W743. doi:10.1093/nar/gkac382
   PubMed Web of Science ®Google Scholar
• Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective Aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007;110(6):2034–2040. doi:10.1182/blood-2007-02-073700
   PubMed Web of Science ®Google Scholar
• Borah NA, Reddy MM. Aurora kinase B inhibition: a potential therapeutic strategy for cancer. Molecules. 2021;26(7):1981. doi:10.3390/molecules26071981
   PubMed Web of Science ®Google Scholar
• Sak A, Stuschke M, Groneberg M, Kübler D, Pöttgen C, Eberhardt WE. Inhibiting the Aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines. Int J Radiat Oncol Biol Phys. 2012;84(2):492–499. doi:10.1016/j.ijrobp.2011.12.021
   PubMed Web of Science ®Google Scholar
• Marampon F, Gravina GL, Popov VM, et al. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Int J Oncol. 2014;44(1):285–294. doi:10.3892/ijo.2013.2167
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Carvajal RD, Midgley R, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):370–380. doi:10.1007/s10637-012-9825-7
   PubMed Web of Science ®Google Scholar
• Cheung CH, Sarvagalla S, Lee JY, Huang YC, Coumar MS. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011–2013). Expert Opin Ther Pat. 2014;24(9):1021–1038. doi:10.1517/13543776.2014.931374
   PubMed Web of Science ®Google Scholar
• Burris HA, Wang JS-Z, Johnson ML, et al. A Phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kinase inhibitor AZD2811 in patients with advanced solid tumours. J clin oncol. 2017;35(15_suppl):TPS2608. doi:10.1200/JCO.2017.35.15_suppl.TPS2608
   Google Scholar
• Loap P, Loirat D, Berger F, et al. Combination of olaparib and radiation therapy for triple negative breast cancer: preliminary results of the RADIOPARP Phase 1 trial. Int J Radiat Oncol Biol Phys. 2021;109(2):436–440. doi:10.1016/j.ijrobp.2020.09.032
   PubMed Web of Science ®Google Scholar
• Loap P, Loirat D, Berger F, et al. Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the Phase 1 olaparib and radiation therapy for triple-negative breast cancer trial. JAMA Oncol. 2022;8(12):1802–1808. doi:10.1001/jamaoncol.2022.5074
   PubMed Web of Science ®Google Scholar
• Ho AY, Barker CA, Arnold BB, et al. A Phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer. 2020;126(4):850–860. doi:10.1002/cncr.32599
   PubMed Web of Science ®Google Scholar
• Bavetsias V, Linardopoulos S. Aurora Kinase Inhibitors: current Status and Outlook. Front Oncol. 2015;5:278. doi:10.3389/fonc.2015.00278
   PubMed Web of Science ®Google Scholar
• Schöffski P, Jones SF, Dumez H, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral Aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer. 2011;47(15):2256–2264. doi:10.1016/j.ejca.2011.07.008
   PubMed Web of Science ®Google Scholar
• Schöffski P, Besse B, Gauler T, et al. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional Phase II study. Ann Oncol. 2015;26(3):598–607. doi:10.1093/annonc/mdu566
   PubMed Web of Science ®Google Scholar
• Carducci M, Shaheen M, Markman B, et al. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Invest New Drugs. 2018;36(6):1060–1071. doi:10.1007/s10637-018-0625-6
   PubMed Web of Science ®Google Scholar
• Floc’h N, Ashton S, Taylor P, et al. Optimizing therapeutic effect of aurora B inhibition in acute myeloid leukemia with AZD2811 nanoparticles. Mol Cancer Ther. 2017;16(6):1031–1040. doi:10.1158/1535-7163.MCT-16-0580
   PubMed Web of Science ®Google Scholar
• Floc’h N, Ashton S, Ferguson D, et al. Modeling dose and schedule effects of AZD2811 nanoparticles targeting aurora B kinase for treatment of diffuse large B-cell lymphoma. Mol Cancer Ther. 2019;18(5):909–919. doi:10.1158/1535-7163.MCT-18-0577
   PubMed Web of Science ®Google Scholar
• Ashton S, Song YH, Nolan J, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016;8(325):325ra317. doi:10.1126/scitranslmed.aad2355
   Web of Science ®Google Scholar